EAST LANSING, Mich., March 23, 2009 (PRIME NEWSWIRE) –Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) is pleased to announce that Dr. Fraser reported this week that his team has “made significant progress on developing enzymes and strategies for conducting site specific genetic recombination in silkworm.”
“In the Company’s view, the development of this particular gene splicing technology is the key to unlocking the tremendous commercial potential of spider silks and other recombinant polymers,” said Kraig’s CEO, Kim K. Thompson. “Dr. Fraser’s report of this news from the laboratory is the culmination of years of scientific effort. It is a huge milestone on the path to commercialization,” continued Thompson.
“We believe that we are the only people who have this capability at this time.” Dr. Fraser emphasized.
Dr. Fraser’s team of research scientists, working within University of Notre Dame laboratories, has reported a number of significant advancements over the last four or five months. This most recent announcement follows closely on the heals of the Company’s announcement that it had achieved approximately five thousand genetic insertions, and that it had achieved the activation of fluorescent marker gene sequences which the researchers incorporated into spider silk DNA packets.
Site specific genetic recombination allows for the genetic targeting of a specific location on a specific chromosome. It is potentially critical to the Company’s work because of the strong influence of what geneticists’ refer to as “location effects.” Location effects are effects that result not from the coding of a specific gene, but from the location of that gene on a specific chromosome.
For more information on Kraig Biocraft Laboratories, please visit the Company’s web site: www.KraigLabs.com
Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believe,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “seen,” “develops”, “researching,” “research,” “potential,” “path,” “progress,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
CONTACT: Kraig Biocraft Laboratories, Inc.
Kim K. Thompson, CEO